Repatha and Paranasal sinus hypersecretion - a phase IV clinical study of FDA data
Paranasal sinus hypersecretion is found among people who take Repatha, especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months.
The phase IV clinical study analyzes which people take Repatha and have Paranasal sinus hypersecretion. It is created by eHealthMe based on reports of 112,588 people who have side effects when taking Repatha from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
112,588 people reported to have side effects when taking Repatha.
Among them, 158 people (0.14%) have Paranasal sinus hypersecretion.
What is Repatha?
Repatha has active ingredients of evolocumab. It is often used in high blood cholesterol. eHealthMe is studying from 112,806 Repatha users for its effectiveness, alternative drugs and more.
What is Paranasal sinus hypersecretion?
Paranasal sinus hypersecretion is found to be associated with 705 drugs and 386 conditions by eHealthMe.
Number of Repatha and Paranasal sinus hypersecretion reports submitted per year:
Time on Repatha when people have Paranasal sinus hypersecretion *:
Gender of people who have Paranasal sinus hypersecretion when taking Repatha*:
Age of people who have Paranasal sinus hypersecretion when taking Repatha *:
Common drugs people take besides Repatha *:
Common side effects people have besides Paranasal sinus hypersecretion *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Repatha and have Paranasal sinus hypersecretion?Check whether Paranasal sinus hypersecretion is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Paranasal sinus hypersecretion and when was it recovered:
Expand to all the drugs that have ingredients of evolocumab:
Alternative drugs to, pros and cons of Repatha:
- Repatha (112,806 reports)
Common Repatha side effects:
Browse all side effects of Repatha:a b c d e f g h i j k l m n o p q r s t u v w x y z
Paranasal sinus hypersecretion treatments and more:
- Paranasal sinus hypersecretion (4,043 reports)
COVID vaccines that are related to Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion in Moderna COVID Vaccine
- Paranasal sinus hypersecretion in Pfizer BioNTech Covid Vaccine
- Paranasal sinus hypersecretion in Johnson and Johnson Covid Vaccine
Common drugs associated with Paranasal sinus hypersecretion:
All the drugs that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (705 drugs)
Common conditions associated with Paranasal sinus hypersecretion:
All the conditions that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (386 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on evolocumab (the active ingredients of Repatha) and Repatha (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Prolia and Gastric Ulcer - 7 seconds ago
- Tylenol and Dyshidrotic Eczema - 10 seconds ago
- Prochlorperazine Maleate and Arterial Stenosis - 11 seconds ago
- Sulindac and Protamine Sulfate drug interaction - 11 seconds ago
- Citalopram Hydrobromide and Troponin I Increased - 13 seconds ago
- Doxazosin Mesylate and Cardiac Murmur - 15 seconds ago
- Primidone and Pancuronium drug interaction - 20 seconds ago
- Metoclopramide Hcl and Hydrochlorothiazide drug interaction - 25 seconds ago
- Astrocytoma, Low Grade and Swelling - 28 seconds ago
- Ritalin and Abdominal Discomfort - 31 seconds ago